2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2714

Investigation of Inactive Disease Activity States Among JIA Patients in the CARRA Registry
Abstract Number: 2715

Incidence of Juvenile Idiopathic Arthritis in the United Kingdom: Estimates from a National Primary Care Dataset
Abstract Number: 2716

Long Term Outcomes of Childhood Onset Rheumatoid Arthritis
Abstract Number: 2717

Long-term Outcome of Juvenile-onset Psoriatic Arthritis
Abstract Number: 2718

A Retrospective Study Comparing Refractoriness to Biologic Disease Modifying Anti-Rheumatic Drugs in Adults with Juvenile Idiopathic Arthritis as Compared to Those with Rheumatoid Arthritis
Abstract Number: 2719

Predictors of Health Care Transition Practices Among North American Pediatric Rheumatology Providers
Abstract Number: 2720

Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution
Abstract Number: 2721

Subjective and Objective Dyscognition in Adolescents with Juvenile Fibromyalgia Syndrome
Abstract Number: 2722

The down Syndrome Arthropathy Cohort in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics, Treatment and Outcomes
Abstract Number: 2723

Alagille Syndrome and Chronic Arthritis: An International Case Series
Abstract Number: 2724

Farber Disease (Acid Ceramidase Deficiency): The First Natural History Study of This Rare Disease Involving Symptoms Which Can Mimic JIA
Abstract Number: 2725

Clinical Factors Distinguishing Between Pediatric Tumors with Arthritis at Onset and JIA: Preliminary Analysis of the ONCOREUM Study
Abstract Number: 2726

Baseline Characteristics and Quality of Life Metrics in Non-Infectious Uveitis
Abstract Number: 2727

Mitochondrial Contribution to Juvenile Dermatomyositis Pathogenesis
Abstract Number: 2728

Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].